Skip to content

Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study

Role of IMP3 Expression in Colorectal Carcinoma: An Immunohistochemical Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05601388
Enrollment
60
Registered
2022-11-01
Start date
2022-10-01
Completion date
2023-06-01
Last updated
2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Colorectal carcinoma (CRC) is the third most common malignancy worldwide. In Egypt, the relative frequency of CRC is about 9-12% with high male predominance 3:1. The high mortality rates associated with CRC is reflective of several factors including: the lack of apparent symptoms in the early stages and the absence of cancer prevention strategies in developing countries. Insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a member of the IMP family which plays a key role in the transfer and stabilization of mRNA, cell growth, and migration during embryogenesis. IMP3 has gained considerable interest as a cancer-associated protein. Previous studies strongly suggest that IMP3 may represent a valuable prognostic marker in human cancer. Its overexpression has been reported in a variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer, gastric cancer, liver cancer, and breast cancer

Detailed description

Colorectal carcinoma (CRC) is the third most common malignancy worldwide. In Egypt, the relative frequency of CRC is about 9-12% with high male predominance 3:1. The high mortality rates associated with CRC is reflective of several factors including: the lack of apparent symptoms in the early stages and the absence of cancer prevention strategies in developing countries. Insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a member of the IMP family which plays a key role in the transfer and stabilization of mRNA, cell growth, and migration during embryogenesis. To date, there are three known members of IMP family proteins: IMP1, IMP2, and IMP3 . IMP3 has gained considerable interest as a cancer-associated protein. Previous studies strongly suggest that IMP3 may represent a valuable prognostic marker in human cancer. Its overexpression has been reported in a variety of human types of cancer, including lung cancer, colon cancer, pancreatic cancer, gastric cancer, liver cancer, and breast cancer It has been reported that IMP3 expression, determined via immunohistochemistry (IHC), has prognostic significance in CRC, recent studies revealed that IMP3 expression in tumor cells is a marker of poor prognosis in CRC patients and promotes tumor cell proliferation, adhesion, and invasion. Despite these observations, the IMP3 expression and its clinicopathologic significance in human CRC needs further elucidation.

Interventions

None listed

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL

Inclusion criteria

* Patients with CRC and will be underwent surgery.

Exclusion criteria

* \- Patients received pre-operative chemotherapy or radiotherapy. * Patients with insufficient clinical data.

Design outcomes

Primary

MeasureTime frameDescription
evaluate the immunohistochemical (IHC) expression of IMP3 in CRC and to correlate its expression with some known clinicopathological parameters.4 monthsIHC

Countries

Egypt

Contacts

Primary ContactNagwa Ahmed, Lecture
nagwa.sadek@med.sohag.edu.eg01017415996

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026